Cigna Corporation reported strong financial results in the second quarter of 2022, with total revenues of $45,480 million and net income of $1,572 million. Comprehensive income rose, driven by factors like unrealized appreciation and depreciation on securities. The balance sheet showed total assets of $152,630 million, liabilities of $106,663 million, and shareholders' equity of $45,892 million. Operating activities generated $3,274 million in cash flow, and investing activities focused on sales and purchases of investments, maintaining the company's strong financial position. The text also delved into the company's liabilities, emphasizing unpaid claims and claim expenses in international operations and joint ventures. Furthermore, it highlighted reinsurance agreements and investments like debt securities, equity securities, and commercial mortgage loans in the company's portfolio, discussing accounting policies and valuation methods utilized.
The text provided is a comprehensive financial breakdown of Cigna Corporation's various business segments, investments, and risk factors as of June 30, 2022. It covers the segmentation of its operations into categories like Evernorth, Cigna Healthcare, Other Operations, and Corporate. Financial metrics such as adjusted revenues, pre-tax adjusted income from operations, and ratios are discussed. Additionally, details on liquidity, capital resources, critical accounting estimates, and market risks are provided. The overall analysis highlights the diverse investments, performance indicators, operational challenges, and strategic initiatives undertaken by Cigna during the first half of 2022.
The text states that information related to market risk can be found in the section titled "Market Risk" in Item 2 above, specifically in the Management's Discussion and Analysis of Financial Condition and Results of Operations.
The text discusses the evaluation of the effectiveness of Cigna's disclosure controls and procedures, indicating that the controls are considered effective by the Chief Executive Officer and Chief Financial Officer. The assessment concludes that the controls ensure timely and accurate disclosure of information required by the Securities and Exchange Commission's rules. Additionally, it states that there have been no significant changes in the internal control over financial reporting that would materially affect Cigna's internal control during the specified period.
The text provided is a mention of legal proceedings in a financial report, indicating that details on legal and regulatory matters can be found in Note 18 of the Consolidated Financial Statements.
The text provided mentions that for information about factors that could impact the company's performance and financial health, one should refer to the risk factors detailed in the Annual Report on Form 10-K for the year ended December 31, 2021.
The text provides information on Cigna's share repurchase activity for the quarter ended June 30, 2022. The table details the total number of shares purchased, average price per share, shares purchased as part of a publicly announced program, and the dollar value of shares yet to be purchased. The company also has an additional share repurchase program authorized by the Board of Directors, allowing for repurchases depending on market conditions and other factors. The authority for share repurchase was $5.3 billion as of August 3, 2022. Employees also tendered shares under the Company's equity compensation plans during this period.
I understand that you will send me the text in parts and would like me to summarize it once I have received all the parts. Please go ahead and provide the text for me to summarize.
I'm ready to assist you with summarizing the text once you provide it.
The text provides detailed financial information regarding Cigna Corporation's operations for the three and six months ended June 30, 2022, compared to the same periods in 2021. It covers various aspects such as pharmacy revenues, adjusted expenses, script volume, generic fill rates, adjusted revenues, and gross profits. Specifically, it discusses specific segments like the Cigna Healthcare Segment, Other Operations, and Corporate, detailing their financial performance, market risks, and control procedures. The information also includes a discussion on investments, market risks, equity securities repurchase activities, governance and control procedures, legal proceedings, and risk factors impacting the company's financial outlook.
The text provided is a list of various exhibits that are related to Cigna Corporation's financial reporting and agreements. It includes items such as a Revolving Credit and Letter of Credit Agreement, certifications of the Chief Executive Officer and Chief Financial Officer, and materials from Cigna Corporation's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. The text concludes with a signature from the Executive Vice President and Chief Financial Officer of Cigna Corporation.
